Comprehensive genome analysis showed that the PI3K/Akt/mTOR pathway is a viable therapeutic target in small cell lung cancer (SCLC), a highly aggressive neuroendocrine tumour. This evidence concerns the gene PIK3CA and small cell lung carcinoma.